Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2025-01-13 Sale |
2025-01-15 5:00 pm |
Regulus Therapeutics Inc. | RGLS | Klassen Preston President & Head of R & D |
31,445 | $1.2632 | $39,721 | 36,055 (Direct) |
View |
| 2023-01-26 Sale |
2023-01-27 4:42 pm |
Metacrine Inc. | MTCR | Klassen Preston President & CEO |
380,605 | $0.4132 | $157,266 | 541,905 (Direct) |
View |
| 2022-04-19 Sale |
2022-04-20 4:25 pm |
Metacrine Inc. | MTCR | Klassen Preston President & CEO |
44,748 | $0.50219 | $22,472 | 922,510 (Direct) |
View |
| 2021-05-20 Purchase |
2021-05-20 6:55 pm |
Metacrine Inc. | MTCR | Klassen Preston President & CEO |
20,547 | $3.6352 | $74,692 | 20,547 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-01-30 Option Award |
2025-01-31 5:00 pm |
N/A 2035-01-29 |
Regulus Therapeutics Inc. | RGLS | Klassen Preston President & Head of R & D |
675,000 | $0 | 675,000 (Direct) |
View |
| 2025-01-09 Option Award |
2025-01-10 5:00 pm |
N/A N/A |
Regulus Therapeutics Inc. | RGLS | Klassen Preston President & Head of R & D |
37,500 | $1.36 | 67,500 (Direct) |
View |
| 2025-01-09 Option Award |
2025-01-10 5:00 pm |
N/A N/A |
Regulus Therapeutics Inc. | RGLS | Klassen Preston President & Head of R & D |
30,000 | $1.3 | 67,500 (Direct) |
View |
| 2024-05-20 Option Award |
2024-05-21 4:22 pm |
N/A 2034-05-19 |
Regulus Therapeutics Inc. | RGLS | Klassen Preston President & Head of R & D |
528,000 | $0 | 528,000 (Direct) |
View |
| 2024-01-12 Option Award |
2024-01-17 5:18 pm |
N/A 2034-01-11 |
Regulus Therapeutics Inc. | RGLS | Klassen Preston President & Head of R & D |
120,000 | $0 | 120,000 (Direct) |
View |
| 2023-08-10 Option Award |
2023-08-14 4:24 pm |
N/A 2033-08-09 |
Regulus Therapeutics Inc. | RGLS | Klassen Preston President & Head of R & D |
225,000 | $0 | 225,000 (Direct) |
View |
| 2023-06-12 Option Award |
2023-06-12 4:48 pm |
N/A 2033-06-11 |
Regulus Therapeutics Inc. | RGLS | Klassen Preston President & Head of R & D |
350,000 | $0 | 350,000 (Direct) |
View |
| 2023-03-23 Option Award |
2023-03-24 12:35 pm |
N/A N/A |
Metacrine Inc. | MTCR | Klassen Preston Director |
842,211 | $0.47 | 1,384,116 (Direct) |
View |
Ownership |
2023-03-21 7:35 pm |
N/A 2033-03-15 |
Zura Bio Ltd | ZURA | Klassen Preston President and COO |
0 | $0 | 476,756 (Direct) |
View |
| 2022-04-14 Option Award |
2022-04-18 5:28 pm |
N/A N/A |
Metacrine Inc. | MTCR | Klassen Preston President & CEO |
104,500 | $0 | 967,258 (Direct) |
View |
| 2022-02-27 Option Award |
2022-03-01 4:56 pm |
N/A 2032-02-26 |
Metacrine Inc. | MTCR | Klassen Preston President & CEO |
842,211 | $0 | 1,704,969 (Direct) |
View |
| 2021-02-10 Option Award |
2021-02-12 5:03 pm |
N/A 2031-02-09 |
Metacrine Inc. | MTCR | Klassen Preston President & CEO |
247,500 | $0 | 247,500 (Direct) |
View |
Ownership |
2020-09-15 4:43 pm |
N/A 2030-06-08 |
Metacrine Inc. | MTCR | Klassen Preston President & CEO |
0 | $0 | 970,822 (Direct) |
View |